Comment on: "Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis".
- Published in:
- 2019
- By:
- Publication type:
- Letter
Works matching IS 11738804 AND DT 2019 AND VI 33 AND IP 5
Results: 13
1
2
Author's Reply to Puértolas-Tena and Pérez-Surio: "Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta-Analysis".
- Published in:
- 2019
- By:
- Publication type:
- Letter
3
Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis.
- Published in:
- 2019
- By:
- Publication type:
- Correction Notice
4
Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 469, doi. 10.1007/s40259-019-00376-z
- By:
- Publication type:
- Article
5
Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 571, doi. 10.1007/s40259-019-00375-0
- By:
- Publication type:
- Article
6
Insulins as Drugs or Biologics in the USA: What Difference Does it Make and Why Does it Matter?
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 447, doi. 10.1007/s40259-019-00374-1
- By:
- Publication type:
- Article
7
Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?".
- Published in:
- 2019
- By:
- Publication type:
- Letter
8
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 539, doi. 10.1007/s40259-019-00370-5
- By:
- Publication type:
- Article
9
The Expanding Class 2 CRISPR Toolbox: Diversity, Applicability, and Targeting Drawbacks.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 503, doi. 10.1007/s40259-019-00369-y
- By:
- Publication type:
- Article
10
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 515, doi. 10.1007/s40259-019-00368-z
- By:
- Publication type:
- Article
11
Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 485, doi. 10.1007/s40259-019-00367-0
- By:
- Publication type:
- Article
12
Factors Influencing Drug Disposition of Monoclonal Antibodies in Inflammatory Bowel Disease: Implications for Personalized Medicine.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 453, doi. 10.1007/s40259-019-00366-1
- By:
- Publication type:
- Article
13
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin<sup>®</sup>), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study.
- Published in:
- BioDrugs, 2019, v. 33, n. 5, p. 555, doi. 10.1007/s40259-019-00363-4
- By:
- Publication type:
- Article